Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $19.3 million.

  • Caribou Biosciences' Accumulated Expenses fell 2396.26% to $19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year decrease of 2396.26%. This contributed to the annual value of $23.6 million for FY2024, which is 1175.77% up from last year.
  • Latest data reveals that Caribou Biosciences reported Accumulated Expenses of $19.3 million as of Q3 2025, which was down 2396.26% from $20.5 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Accumulated Expenses ranged from a high of $25.4 million in Q3 2024 and a low of $11.2 million during Q1 2022
  • Moreover, its 5-year median value for Accumulated Expenses was $17.2 million (2022), whereas its average is $17.6 million.
  • In the last 5 years, Caribou Biosciences' Accumulated Expenses skyrocketed by 5138.71% in 2024 and then plummeted by 2396.26% in 2025.
  • Over the past 5 years, Caribou Biosciences' Accumulated Expenses (Quarter) stood at $13.1 million in 2021, then rose by 22.4% to $16.1 million in 2022, then skyrocketed by 31.44% to $21.1 million in 2023, then rose by 11.76% to $23.6 million in 2024, then dropped by 18.08% to $19.3 million in 2025.
  • Its last three reported values are $19.3 million in Q3 2025, $20.5 million for Q2 2025, and $19.9 million during Q1 2025.